Clinical Trial Update: IMC-A12 in Treating Young Patients With Relapsed or Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor or Other Solid Tumor [Phase 1]

View source ↗

Summary

This is a completed Phase 1 clinical trial evaluating IMC-A12 (cixutumumab) in young patients with relapsed or refractory Ewing sarcoma/Peripheral primitive neu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Childhood Solid Tumor
• Ewing Sarcoma
• Peripheral Primitive Neuroectodermal Tumor

Drugs mentioned

• IMC-A12 (cixutumumab) (cixutumumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Unspecified Childhood Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED